Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae.
Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae.
复制标题
DOI:
10.1080/14756366.2021.1991336
复制
发表时间:
2022-12
影响因子:
5.6
通讯作者:
Flaherty DP
中科院分区:
文献类型:
--
作者:
Abutaleb NS;Elhassanny AEM;Nocentini A;Hewitt CS;Elkashif A;Cooper BR;Supuran CT;Seleem MN;Flaherty DP
Neisseria gonorrhoeae is a high-priority pathogen of concern due to the growing prevalence of resistance development against approved antibiotics. Herein, we report the anti-gonococcal activity of ethoxzolamide, the FDA-approved human carbonic anhydrase inhibitor. Ethoxzolamide displayed an MIC50, against a panel of N. gonorrhoeae isolates, of 0.125 µg/mL, 16-fold more potent than acetazolamide, although both molecules exhibited almost similar potency against the gonococcal carbonic anhydrase enzyme (NgCA) in vitro. Acetazolamide displayed an inhibition constant (Ki) versus NgCA of 74 nM, while Ethoxzolamide’s Ki was estimated to 94 nM. Therefore, the increased anti-gonococcal potency of ethoxzolamide was attributed to its increased permeability in N. gonorrhoeae as compared to that of acetazolamide. Both drugs demonstrated bacteriostatic activity against N. gonorrhoeae, exhibited post-antibiotic effects up to 10 hours, and resistance was not observed against both. Taken together, these results indicate that acetazolamide and ethoxzolamide warrant further investigation for translation into effective anti-N. gonorrhoeae agents.
登录
查看更多内容
影响因子:
2.7
作者:
Abutaleb NS;Elhassanny AEM;Flaherty DP;Seleem MN
通讯作者:
Seleem MN
影响因子:
4
作者:
Davis, Tony D.;Gerry, Christopher J.;Tan, Derek S.
通讯作者:
Tan, Derek S.
影响因子:
4.9
作者:
Binet, Rachel;Maurelli, Anthony T.
通讯作者:
Maurelli, Anthony T.
影响因子:
6.7
作者:
Elsebaei, Mohamed M.;Abutaleb, Nader S.;Mayhoub, Abdelrahman S.
通讯作者:
Mayhoub, Abdelrahman S.
影响因子:
5.2
作者:
Camara, Jordi;Serra, Judit;Ardanuy, Carmen
通讯作者:
Ardanuy, Carmen